Unit­ed Ther­a­peu­tics bags a new OK on Ty­va­so, with block­buster ex­pec­ta­tions; Gilead goes back to Ab­Celler­a's well with a set of fresh tar­gets

As ex­pect­ed, Unit­ed Ther­a­peu­tics {UTHR} snagged an OK from the FDA to sell the in­haled ver­sion of its block­buster drug Ty­va­so for a new in­di­ca­tion: pul­monary hy­per­ten­sion as­so­ci­at­ed with in­ter­sti­tial lung dis­ease. And as ex­pect­ed, they im­me­di­ate­ly launched their new mar­ket­ing ef­fort af­ter care­ful­ly lay­ing the ground­work.

Unit­ed COO Michael Benkowitz not­ed:

We’ve al­ready ex­pand­ed our field-based teams by 40% to ed­u­cate the ILD com­mu­ni­ty on the ben­e­fits of Ty­va­so and how to prop­er­ly di­ag­nose PH-ILD. We ex­pect rapid up­take of Ty­va­so in this in­di­ca­tion and ex­pect to dou­ble the num­ber of pa­tients on Ty­va­so ther­a­py by the end of 2022, bar­ring any COVID-re­lat­ed de­lays.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER